Determinants of functionality level of farmers training centers in north-west Ethiopia.

The Ethiopian agricultural extension system is highly dependent on Farmers/Pastoralists Training Centers (F/PTCs), hereinafter training centers simply. These training centers are established at Kebele level mainly to provide advisory, information, demonstration, and training services to farmers and pastoralists. Nationally, the training centers are categorized into four levels based on their functionality level.

Training at farmers training centers and its impact on crop productivity and households' income in Ethiopia: A propensity score matching (PSM) analysis.

The creation and expansion of training and extension networks for rural households are indispensable to develop and improve skills and to increase productivity and income-generating capabilities. In this line, Ethiopia has established farmers/pastoralists training centers (F/PTCs) since 2002 aimed at providing a multitude of services to farmers at the grassroots level. One of these services is the provision of training.

The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study.

Idasanutlin, an MDM2 antagonist, showed clinical activity and a rapid reduction in JAK2 V617F allele burden in patients with polycythemia vera (PV) in a phase 1 study. This open-label phase 2 study evaluated idasanutlin in patients with hydroxyurea (HU)-resistant/-intolerant PV, per the European LeukemiaNet criteria, and phlebotomy dependence; prior ruxolitinib exposure was permitted. Idasanutlin was administered once daily on days 1 through 5 of each 28-day cycle.

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.

Background: Emactuzumab is a monoclonal antibody against the colony-stimulating factor-1 receptor and targets tumor-associated macrophages (TAMs). This study assessed the safety, clinical activity, pharmacokinetics (PK) and pharmacodynamics (PD) of emactuzumab, as monotherapy and in combination with paclitaxel, in patients with advanced solid tumors.

Patients And Methods: This open-label, phase Ia/b study comprised two parts (dose escalation and dose expansion), each containing two arms (emactuzumab, every 2 or 3 weeks, as monotherapy or in combination with paclitaxel 80 mg/m2 weekly).